GlassScriptPhysician profile
Kevin Michael Gallagher
NPI 1275776718
$145,232.71
in general payments reported to CMS, 2019-2025
53 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,665 · 2022: $17K · 2023: $36K · 2024: $50K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $96K · Travel and Lodging: $12K · Food and Beverage: $11K · Consulting Fee: $6,294 · Education: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,658.13 |
| Travel and Lodging | $12,211.90 |
| Food and Beverage | $11,224.43 |
| Consulting Fee | $6,294.00 |
| Education | $685.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66,884.86 | 2021-2025 | Lynparza, Imfinzi, Imjudo |
| Genentech USA, INC. | $29,806.32 | 2022-2025 | Tecentriq, Polivy, Phesgo |
| Merck Sharp & Dohme LLC | $28,252.34 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Dendreon Pharmaceuticals LLC | $11,198.51 | 2024-2025 | Provenge |
| Daiichi Sankyo INC. | $1,539.88 | 2022-2025 | Injectafer, Enhertu, Vanflyta |
| Janssen Biotech, INC. | $1,142.74 | 2022-2025 | Erleada, Darzalex, Akeega |
| Novartis Pharmaceuticals Corporation | $1,043.77 | 2022-2025 | |
| Abbvie INC. | $517.22 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $386.11 | 2023 | Precisetumor |
| Janssen Scientific Affairs, LLC | $385.83 | 2024-2025 | Talvey, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $350.99 | 2022-2025 | |
| Astellas Pharma US INC | $335.98 | 2023-2025 | Xtandi |
| Gilead Sciences, INC. | $298.72 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $274.37 | 2022-2024 | Opdivo |
| Celgene Corporation | $267.91 | 2022-2025 | Reblozyl, Pomalyst |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $241.47 | 2023-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $231.23 | 2022-2023 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $203.95 | 2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $155.83 | 2022-2024 | |
| Pfizer INC. | $152.39 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $138.41 | 2022-2025 | Libtayo |
| Seagen INC. | $129.59 | 2023-2025 | Adcetris |
| Amgen INC. | $115.83 | 2022-2023 | Kyprolis, Nplate, Xgeva |
| Eisai INC. | $113.33 | 2022-2025 | |
| Incyte Corporation | $100.53 | 2022-2023 | Jakafi |
| Beigene USA, INC. | $79.75 | 2022-2023 | Brukinsa |
| Tempus Ai, INC | $76.83 | 2024-2025 | Xt Cdx |
| Emd Serono, INC. | $63.87 | 2022-2023 | Bavencio |
| Mirati Therapeutics, INC. | $60.88 | 2023 | Krazati |
| Immunocore Limited | $50.73 | 2025 | Kimmtrak |
| Glaxosmithkline, LLC. | $50.33 | 2022-2023 | Zejula, Jemperli |
| Karyopharm Therapeutics INC. | $43.99 | 2022-2023 | Xpovio |
| Sobi, INC | $42.42 | 2022-2023 | |
| Kite Pharma, INC. | $42.30 | 2022-2023 | Yescarta |
| Puma Biotechnology, INC. | $39.76 | 2022-2023 | |
| Taiho Oncology, INC. | $37.32 | 2022-2025 | |
| Adc Therapeutics America, INC. | $35.06 | 2023 | |
| Recordati_rare_diseases_inc. | $35.06 | 2023-2025 | Sylvant |
| Jazz Pharmaceuticals INC. | $32.80 | 2023 | |
| Morphosys, US INC. | $32.30 | 2023 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $29.58 | 2023-2024 | Onivyde, Somatuline Depot, Tazverik |
| Menarini Silicon Biosystems, INC. | $26.24 | 2024 | |
| Lilly USA, LLC | $21.40 | 2022 | |
| Foundation Medicine, INC. | $20.94 | 2023 | |
| Progenics Pharmaceuticals, INC. | $20.93 | 2023 | Pylarify |
| Genmab U.S., INC. | $17.78 | 2024 | Epkinly |
| Servier Pharmaceuticals LLC | $17.29 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.74 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $15.32 | 2023 | Alunbrig |
| Springworks Therapeutics, INC. | $14.75 | 2024 | Ogsiveo |
| Blueprint Medicines Corporation | $13.94 | 2022 | |
| Aveo Pharmaceuticals, INC. | $13.90 | 2025 | |
| G1 Therapeutics, INC. | $13.39 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.